Abstract
Background and aims: Peptydil prolyl cis-trans isomerase (PIN-1), which specifically regulates the conformational changes following phosphorylation of several proteins, targets the inactive hyperphosphorylated tau on the Thr231-Pro motif and directly restores its biological function. Interestingly, PIN-1 is oxidatively inhibited not only in Alzheimer’s disease brain but also in the hippocampi of mild cognitive impairment (MCI) subjects. The PIN-1 gene is characterized by two single nucleotide polymorphisms (SNPs) in the promoter region which are associated with the risk of Alzheimer’s disease. The aim of this study was to analyse the genotype and allele distributions of these PIN-1 SNPs in MCI subjects diagnosed respectively as amnestic MCI (a-MCI) and multiple impaired cognitive domains (mcd-MCI) on the basis of cognitive features. Methods: −667 T/C and −842 C/G SNPs were genotyped by polymerase chain reaction (PCR) amplification and direct sequencing in 43 MCI subjects, with the intention of comparing −667 and −842 SNP frequencies with those previously described in 111 Alzheimer’s disease patients (AD) and 73 healthy controls (HC). Results: The allele frequencies of the −842 C/G SNP in a-MCI subjects are similar to those of AD subjects, while those of mcd-MCI are comparable to HC (G allele 83% in both a-MCI and AD; 95% and 94% in mcd-MCI and HC, respectively). A similar trend is also observed in −842 C/G genotypes. Conclusions: Since a-MCI is thought to be the preclinical form of AD, the similar genotype distribution of −842 SNP in AD and a-MCI, but not in mcd-MCI, suggests that it is potentially involved in the conversion of a-MCI to AD. In conclusion, these findings support the theory that polymorphisms of the PIN-1 gene can affect neurodegeneration and its clinical progression.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Price JL, Morris JC. Tangles and plaques in non demented aging and “preclinical” Alzheimer’s disease. Ann Neurol 1999; 45: 358–68.
Petersen RC, Doody R, Kurz A, et al. Current concepts in mild cognitive impairment. Arch Neurol 2001; 5: 1985–92.
Alonso ADC, Grundke-Iqbal I, Iqbal K. Alzheimer’s disease hyperphosphorylated Tau sequesters normal Tau into tangles of filaments and disassembles microtubules. Nature Med 1996; 2: 783–7.
Hansson O, Zettenberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006; 5: 228–34.
Lu PJ, Wulf G, Zhou XZ, Davies P, Lu KP. The prolyl isomerase PIN-1 restores the function of Alzheimer-associated phosphorylated Tau protein. Nature 1999; 399: 784–8.
Butterfield DA, Poon HF, St. Clair D, et al. Redox proteomics identification of oxidatively modified hippocampal proteins in mild cognitive impairment: insights into the development of Alzheimer’s disease. Neurobiol Dis 2006; 22: 223–32.
Wijsman EM, Daw EW, Yu CE, et al. Evidence for a novel late-onset Alzheimer disease locus on chromosome 19p13. 2. Am J Hum Genet 2004; 75: 398–409.
Segat L, Pontillo A, Annoni G, et al. PIN-1 promoter polymorphisms are associated with Alzheimer’s disease. Neurobiol Ageing 2007; 28: 69–74.
Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999; 56: 303–8.
Zanetti M, Ballabio C, Abbate C, Cutaia C, Vergani C, Bergamaschini L. Mild cognitive impairment subtypes and vascular dementia in community-dwelling elderly people: a 3-year follow-up study. JAGS 2006; 54: 580–6.
Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006; 5: 228–34.
McKhan G, Drachman D, Folstein M, Katzman R, Proce D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease. Neurology 1984; 34: 939–44.
Singh PP, Singh M, Mastana SS. APOE distribution in world populations with new data from India and the UK. Ann Hum Biol 2006; 33: 279–308.
Lee VM, Goedert M, Trojanowski JQ. Neurodegenerative tauopathies. Annu Rev Neurosci 2001; 24: 1121–59.
Lee MS, Kao SC, Lemere CA, et al. APP processing is regulated by cytoplasmic phosphorylation. J Cell Biol 2003; 163: 83–95.
LU KP, Liou YC, Vincent I. Proline-directed phosphorylation and isomerization in mitotic regulation and in Alzheimer’s disease. BioEssays 2003; 25: 174–81.
Liou YC, Sun A, Ryo A, et al. Role of the prolyl isomerase PIN-1 in protecting against age-dependent neurodegeneration. Nature 2003; 424: 556–61.
Pastorino L, Anyang S, Lu PJ, et al. The prolyl isomerase Pin1 regulates amyloid precursor protein processing and Abeta production. Nature 2006; 440: 528–34.
Hutton M. Missense and splice site mutations in Tau associated with FTDP-17: multiple pathogenic mechanisms. Neurology 2001; 11: S21–5.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Arosio, B., Segat, L., Milanese, M. et al. PIN-1 promoter polymorphisms in mild cognitive impairment and susceptibility to Alzheimer’s disease: a preliminary report. Aging Clin Exp Res 19, 406–409 (2007). https://doi.org/10.1007/BF03324722
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03324722